{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:22:15Z","timestamp":1787440935608,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC010030"],"award-info":[{"award-number":["ZIA BC010030"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-T1137809"],"award-info":[{"award-number":["TCVGH-T1137809"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114-2320-B-182-005"],"award-info":[{"award-number":["114-2320-B-182-005"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2320-B-182-018"],"award-info":[{"award-number":["112-2320-B-182-018"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPD1P0151"],"award-info":[{"award-number":["CMRPD1P0151"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["BMRPC17"],"award-info":[{"award-number":["BMRPC17"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPD1M0582"],"award-info":[{"award-number":["CMRPD1M0582"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119613","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:50:29Z","timestamp":1781002229000},"page":"119613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Attenuation of ABCG2-dependent drug efflux by befotertinib restores chemosensitivity in multidrug-resistant non-small cell lung cancer cells"],"prefix":"10.1016","volume":"200","author":[{"given":"Yen-Ching","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4547-3434","authenticated-orcid":false,"given":"Ting-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Chiau","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Huan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tzu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Ho","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-4955","authenticated-orcid":false,"given":"Suresh.V.","family":"Ambudkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2434-3361","authenticated-orcid":false,"given":"Chung-Pu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.biopha.2026.119613_bib1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","article-title":"Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters","volume":"23","author":"Sajid","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2026.119613_bib2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119613_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119613_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-60761-416-6_4","article-title":"Mechanisms of multidrug resistance in cancer","volume":"596","author":"Gillet","year":"2010","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119613_bib5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1158\/1078-0432.CCR-0937-3","article-title":"Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer","volume":"10","author":"Yoh","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119613_bib6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2008.07.014","article-title":"Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy","volume":"64","author":"Ota","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.biopha.2026.119613_bib7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fphar.2019.00208","article-title":"Inhibitors of human ABCG2: from technical background to recent updates with clinical implications","volume":"10","author":"Toyoda","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119613_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100681","article-title":"Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update","volume":"49","author":"Dong","year":"2020","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.biopha.2026.119613_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101011","article-title":"Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2","volume":"71","author":"Wu","year":"2023","journal-title":"Drug. Resist. Updat."},{"issue":"10","key":"10.1016\/j.biopha.2026.119613_bib10","first-page":"1192","article-title":"Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M-mutated NSCLC that had progressed after prior egfr tyrosine kinase inhibitor therapy: a phase 2, multicenter, single-arm, open-label study","volume":"17","author":"Lu","year":"2022","journal-title":"J. Thoracic Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.119613_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/oncolo\/oyab007","article-title":"Phase I trial of a third generation EGFR mutant-selective inhibitor (D-0316) in patients with advanced non-small cell lung cancer","volume":"27","author":"Jian","year":"2022","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.biopha.2026.119613_bib12","first-page":"473","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer, nature reviews","volume":"11","author":"Camidge","year":"2014","journal-title":"Clin. Oncol."},{"issue":"15","key":"10.1016\/j.biopha.2026.119613_bib13","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s40265-023-01946-w","article-title":"Befotertinib: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2026.119613_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.21037\/cco-24-50","article-title":"Befotertinib: one more drug targeting EGFR-the more may be the merrier","volume":"14","author":"Sacchi de Camargo Correia","year":"2025","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119613_bib15","article-title":"Efficacy of befotertinib in non-small cell lung cancer harboring uncommon compound EGFR mutations G719X and S768I: a case report","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119613_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.21037\/cco-24-19","article-title":"Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile","volume":"13","author":"Sorensen","year":"2024","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119613_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107901","article-title":"Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial","volume":"195","author":"Lu","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.biopha.2026.119613_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","article-title":"Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents","volume":"142","author":"Beretta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"12 Pt 1","key":"10.1016\/j.biopha.2026.119613_bib19","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/1535-7163.MCT-07-0352","article-title":"New inhibitors of ABCG2 identified by high-throughput screening","volume":"6","author":"Henrich","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119613_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0005-2736(01)00308-X","article-title":"A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2)","volume":"1512","author":"Robey","year":"2001","journal-title":"Biochim. Et. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.biopha.2026.119613_bib21","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6601370","article-title":"Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity","volume":"89","author":"Robey","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2026.119613_bib22","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/cancers12061366","article-title":"Erdafitinib resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs","volume":"12","author":"Wu","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119613_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114516","article-title":"The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs","volume":"188","author":"Wu","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119613_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1021\/acsptsci.3c00217","article-title":"Epidermal growth factor receptor inhibitor mobocertinib resensitizes multidrug-resistant cancer cells by attenuating the human ATP-binding cassette subfamily b member 1 and subfamily G member 2","volume":"7","author":"Li","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"18","key":"10.1016\/j.biopha.2026.119613_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813972","article-title":"Furmonertinib, a third-generation EGFR tyrosine kinase inhibitor, overcomes multidrug resistance through inhibiting ABCB1 and ABCG2 in cancer cells","volume":"24","author":"Wu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119613_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117542","article-title":"Epertinib counteracts multidrug resistance in cancer cells by antagonizing the drug efflux function of ABCB1 and ABCG2","volume":"180","author":"Lin","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.biopha.2026.119613_bib27","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/0008-5472.CAN-03-3298","article-title":"Pheophorbide a is a specific probe for ABCG2 function and inhibition","volume":"64","author":"Robey","year":"2004","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119613_bib28","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1073\/pnas.97.6.2515","article-title":"Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein","volume":"97","author":"Sauna","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2026.119613_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2213437120","article-title":"Differential dynamics and direct interaction of bound ligands with lipids in multidrug transporter ABCG2","volume":"120","author":"Rasouli","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119613_bib30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ejmech.2019.06.066","article-title":"Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance","volume":"179","author":"Cai","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"18","key":"10.1016\/j.biopha.2026.119613_bib31","first-page":"4559","article-title":"Overexpression of the BCRP\/MXR\/ABCP gene in a topotecan-selected ovarian tumor cell line","volume":"59","author":"Maliepaard","year":"1999","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119613_bib32","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/jpet.103.063149","article-title":"ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins","volume":"310","author":"Bates","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119613_bib33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-018-0775-3","article-title":"Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer"},{"issue":"21","key":"10.1016\/j.biopha.2026.119613_bib34","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1016\/j.bmcl.2012.09.012","article-title":"Downregulation of mdr1 and abcg2 genes is a mechanism of inhibition of efflux pumps mediated by polymeric amphiphiles","volume":"22","author":"Cuestas","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.biopha.2026.119613_bib35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bcp.2012.12.006","article-title":"The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms","volume":"85","author":"Natarajan","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119613_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1006\/bbrc.2001.5130","article-title":"Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells","volume":"285","author":"Ozvegy","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119613_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbamem.2004.11.005","article-title":"Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition","volume":"1668","author":"Ozvegy-Laczka","year":"2005","journal-title":"Biochim. Et. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.biopha.2026.119613_bib38","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/s41467-020-16155-2","article-title":"ABCG2 transports anticancer drugs via a closed-to-open switch","volume":"11","author":"Orlando","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2026.119613_bib39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1023\/A:1012866803188","article-title":"Overview: ABC transporters and human disease","volume":"33","author":"Gottesman","year":"2001","journal-title":"J. Bioenerg. Biomembr."},{"issue":"2","key":"10.1016\/j.biopha.2026.119613_bib40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cn100078a","article-title":"The \"specific\" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP\/ABCG2)","volume":"2","author":"Kannan","year":"2011","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119613_bib41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1124\/jpet.115.225482","article-title":"The inhibitor Ko143 is not specific for ABCG2","volume":"354","author":"Weidner","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2026.119613_bib42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-319-42934-2_6","article-title":"Gene therapeutic approaches to overcome ABCB1-mediated drug resistance","volume":"209","author":"Lage","year":"2016","journal-title":"Recent. Results Cancer Res."},{"issue":"21-22","key":"10.1016\/j.biopha.2026.119613_bib43","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1007\/s00018-021-03901-y","article-title":"Multidrug efflux transporter ABCG2: expression and regulation","volume":"78","author":"Kukal","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119613_bib44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00280-009-1042-5","article-title":"A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts","volume":"65","author":"Endo","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119613_bib45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-015-0362-9","article-title":"FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance","volume":"14","author":"Westover","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2026.119613_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100777","article-title":"Novel nanomedicines to overcome cancer multidrug resistance","volume":"58","author":"Su","year":"2021","journal-title":"Drug. Resist. Updat."},{"issue":"1","key":"10.1016\/j.biopha.2026.119613_bib47","first-page":"41","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev."},{"key":"10.1016\/j.biopha.2026.119613_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102693","article-title":"Does drug repurposing bridge the gaps in management of Parkinson's disease? Unravelling the facts and fallacies","volume":"105","author":"Bashir","year":"2025","journal-title":"Ageing Res. Rev."},{"issue":"6","key":"10.1016\/j.biopha.2026.119613_bib49","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1021\/acs.molpharmaceut.6b00249","article-title":"Osimertinib (AZD9291) attenuates the function of multidrug resistance-linked ATP-binding cassette transporter ABCB1 in vitro","volume":"13","author":"Hsiao","year":"2016","journal-title":"Mol. Pharm."},{"issue":"12 Pt 1","key":"10.1016\/j.biopha.2026.119613_bib50","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1535-7163.MCT-07-2005","article-title":"Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter","volume":"6","author":"Wu","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.biopha.2026.119613_bib51","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1096\/fj.201902338RR","article-title":"ABCG2 requires a single aromatic amino acid to \"clamp\" substrates and inhibitors into the binding pocket","volume":"34","author":"Gose","year":"2020","journal-title":"Faseb J."},{"issue":"21","key":"10.1016\/j.biopha.2026.119613_bib52","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1158\/1078-0432.CCR-18-0851","article-title":"Nilotinib as co-adjuvant treatment with doxorubicin in patients with sarcomas: a phase I trial of the Spanish Group for Research on Sarcoma","volume":"24","author":"Alemany","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119613_bib53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/17425255.2019.1591373","article-title":"ABCG2\/BCRP: variants, transporter interaction profile of substrates and inhibitors","volume":"15","author":"Safar","year":"2019","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119613_bib54","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1021\/mp200240a","article-title":"Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions","volume":"8","author":"Gillet","year":"2011","journal-title":"Mol. Pharm."},{"issue":"20","key":"10.1016\/j.biopha.2026.119613_bib55","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1158\/0008-5472.CAN-04-0096","article-title":"Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice","volume":"64","author":"Stewart","year":"2004","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119613_bib56","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1158\/0008-5472.CAN-05-2915","article-title":"Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo","volume":"66","author":"Leggas","year":"2006","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119613_bib57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/17425255.4.2.205","article-title":"Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges","volume":"4","author":"Shukla","year":"2008","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"issue":"20","key":"10.1016\/j.biopha.2026.119613_bib58","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1182\/blood-2010-09-304311","article-title":"Dismounting the MDR horse","volume":"116","author":"Libby","year":"2010","journal-title":"Blood"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226006499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:50:29Z","timestamp":1787439029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226006499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":58,"alternative-id":["S0753332226006499"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119613","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Attenuation of ABCG2-dependent drug efflux by befotertinib restores chemosensitivity in multidrug-resistant non-small cell lung cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119613"}}